Richard Heyman
InvestorVenture Partner at ARCH Venture Partners
Encinitas, California
Writes $50K β $150M checks Β· typically $25M
Experience
- Pelage PharmaceuticalsBoard Membercurrent2025 β present
- Architect TherapeuticsChairman of the BOD and Co-Foundercurrent2023 β present
- ORIC PharmaceuticalsChairman of the BODcurrent2014 β presentSouth San Francisco
- Enliven TherapeuticsBOD Member/Chairmancurrent2020 β present
- Vividion Therapeutics, Inc.BOD member/Former Chairmancurrent2018 β present
- PMV Pharmaceuticals, Inc.Chairman of the Boardcurrent2020 β present
- ARCH Venture PartnersVenture Partnercurrent2020 β present
- Nextech InvestScience Partnercurrent2022 β present
- Salk Institute for Biological StudiesMember Board of Trusteescurrent2015 β presentLa Jolla, CA
- CureboundBoard Member and Scientific Advisory Board Membercurrent2021 β present
- Life Science Cares San DiegoBoard of Managerscurrent2020 β present
- RayzeBioChairman of the Board2022 β 2023
- Metacrine Inc.Executive Chairman2015 β 2022San Diego
- Amunix PharmaceuticalsChairperson of the Board2019 β 2021
- Yumanity TherapeuticsBOD Member2016 β 2021Cambridge, Ma
- Gritstone OncologyBOD Member2015 β 2021Emeryville, CA
- Seragon PharmaceuticalsPresident and CEO2013 β 2015
- Aragon PharmaceuticalsPresident and CEO2009 β 2013
- Kalypsys, Inc.Chief Scientific Officer2006 β 2008
- Exelixis, Inc.Sr. Vice President2004 β 2006
Education
- University of MinnesotaPhD, Pharmacology1980 β 1986
Skills & more
Drug Discovery99Biotechnology79Lifesciences25Molecular Biology28Biochemistry24Pharmacology51Clinical Development38Drug Development82Cell Culture18Oncology30Pharmaceutical Industry51Cell Biology21
+3 more
In VitroAssay DevelopmentIn VivoFrom Richard's professional profile.
Same school
Also attended University of Minnesota82
Madeline PopeSenior Associate, Platform & Marketing at March Capital PartnersNate LeeFounder and Chief Information Security Officer at Scale Venture PartnersJohn BergstromInvestor at Mairs & Power VCMark GorenbergInvestor at Zetta Venture PartnersRobin BorgInvestor at TRANSFORMATION CAPITALKelsey BolanderAssociate β Business Ops & Partner Support at Energize Ventures
+ 76 more
Shared employers
Also worked at Vividion Therapeutics, Inc.2
Also worked at PMV Pharmaceuticals, Inc.1
Also worked at ARCH Venture Partners25
Steve GillisManaging Director at ARCH Venture PartnersCarol SuhPartner at ARCH Venture PartnersSean KendallPartner (Europe) at ARCH Venture PartnersCorey RitterPartner at ARCH Venture PartnersLuciana BorioVenture Partner at ARCH Venture PartnersJoseph JeongVenture Partner at ARCH Venture Partners
+ 19 more
Also worked at Salk Institute for Biological Studies6
Brittany de KouchkovskyDirector, University Relations at Osage University PartnersMira ChaurushiyaManaging Director at Westlake Village BioPartnersPaolo Di GiorgioCEO and Managing Director at Angelini VenturesKatherine ArnoldAnalyst at Ajax HealthKellen HainesVice President at K1 Investment ManagementMichael SmithGeneral Partner at Regeneration.VC
Deals Β· 3
Enliven Therapeutics, Inc.Board seat
via ARCH Venture Partners Β· filed Apr 2024 Β· $90M raise
Vividion TherapeuticsBoard seat
via ARCH Venture Partners Β· filed May 2019 Β· $82M raise
MetacrineBoard seat
via ARCH Venture Partners Β· filed Nov 2016 Β· $37.8M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at ARCH Venture Partners
Ari Nowacek
Partner at ARCH Venture Partners
Axel Bouchon
Venture Partner at ARCH Venture Partners
Brian Cuneo
Senior Partner at ARCH Venture Partners
Carol Suh
Partner at ARCH Venture Partners
Clinton Bybee
Co-founder & Managing Director, Emeritus at ARCH Venture Partners
Corey Ritter
Partner at ARCH Venture Partners
David Moore
Senior Partner at ARCH Venture Partners
George Scangos
Venture Partner at ARCH Venture Partners






















